Abstract
The biological effects of radiation affect both neoplastic and normal tissues. The nature and extent of such effects, however, depend on selected biological parameters (e.g., oxygen supply, cell cycle) and can be modified by chemical agents such as radiosensitizers, radioprotectors and chemotherapeutic agents. A precise control of the mode of action of the radiation is important in order to achieve the maximum effect on tumor tissue, while minimizing the effect on normal tissues. Most of the known and routinely used radiosensitizers are neither selective nor tumor specific. This article reviews a new selective and specific modality that increases the sensitivity of solid tumor tissue, especially of radio resistant, hypoxic tumor cells, to radiation. This modality is currently under early clinical evaluation and encompasses the application of Photofrin II, which is already used as a photosensitizer in photodynamic therapy (PDT) at predetermined times prior to irradiation.
Keywords: Porphyrins, encompasses, photosensitizer, hypoxic, Photofrin
Current Pharmaceutical Design
Title: Porphyrins as Radiosensitizing Agents for Solid Neoplasms
Volume: 9 Issue: 25
Author(s): M. Schaffer, B. Ertl-Wagner, P. M. Schaffer, U. Kulka, A. Hofstetter, E. Duhmke and G. Jori
Affiliation:
Keywords: Porphyrins, encompasses, photosensitizer, hypoxic, Photofrin
Abstract: The biological effects of radiation affect both neoplastic and normal tissues. The nature and extent of such effects, however, depend on selected biological parameters (e.g., oxygen supply, cell cycle) and can be modified by chemical agents such as radiosensitizers, radioprotectors and chemotherapeutic agents. A precise control of the mode of action of the radiation is important in order to achieve the maximum effect on tumor tissue, while minimizing the effect on normal tissues. Most of the known and routinely used radiosensitizers are neither selective nor tumor specific. This article reviews a new selective and specific modality that increases the sensitivity of solid tumor tissue, especially of radio resistant, hypoxic tumor cells, to radiation. This modality is currently under early clinical evaluation and encompasses the application of Photofrin II, which is already used as a photosensitizer in photodynamic therapy (PDT) at predetermined times prior to irradiation.
Export Options
About this article
Cite this article as:
Schaffer M., Ertl-Wagner B., Schaffer M. P., Kulka U., Hofstetter A., Duhmke E. and Jori G., Porphyrins as Radiosensitizing Agents for Solid Neoplasms, Current Pharmaceutical Design 2003; 9 (25) . https://dx.doi.org/10.2174/1381612033454153
DOI https://dx.doi.org/10.2174/1381612033454153 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design Heterocycles in the Treatment of Neglected Tropical Diseases
Current Medicinal Chemistry Exploration of Metastasis-related Proteins as Biomarkers and Therapeutic Targets in the Treatment of Head and Neck Cancer
Current Cancer Drug Targets Natural Compounds and Drug Discovery: Can Cnidarian Venom Play a Role?
Central Nervous System Agents in Medicinal Chemistry Clinical, Prognostic and Therapeutic Significance of Heat Shock Proteins in Cancer
Current Drug Targets The Complexity of Omega-3 Fatty Acid Modulation of Signaling Pathways Related to Pancreatic Cancer
Current Medicinal Chemistry Unequivocal Role of Pyrazine Ring in Medicinally Important Compounds: A Review
Mini-Reviews in Medicinal Chemistry Versatile Applications of microRNA in Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers
Current Drug Discovery Technologies LPS/TLR4 Pathways in Breast Cancer: Insights into Cell Signalling
Current Medicinal Chemistry Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
Current Cancer Drug Targets The Optimal Diagnosis of Urothelial Carcinoma of the Bladder
Current Cancer Therapy Reviews Potential Targets of P. acnes for New Treatments of P. acnes-Associated Diseases
Current Proteomics Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>®</sup>) in the Palliative Treatment of Pancreatic Cancer
Current Medicinal Chemistry Lipids at the Cross-road of Autoimmunity in Multiple Sclerosis
Current Medicinal Chemistry Inducible Nitric Oxide Synthase-Vascular Endothelial Growth Factor Axis: A Potential Target to Inhibit Tumor Angiogenesis by Dietary Agents
Current Cancer Drug Targets Dexamethasone Reduces Cell Adhesion and Migration of T47D Breast Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Radiotherapy in Transitional Cell Carcinoma of Urinary Bladder Cancer –Where Does it Fit Into Treatment Protocol
Current Cancer Therapy Reviews miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke
MicroRNA Pharmacometrics in Dose Finding or Dose Optimization of Anti-Retroviral and Anti-Tubercular Drugs
Infectious Disorders - Drug Targets New Features in the Treatment of Androgen-Independent Prostate Cancer
Current Pharmaceutical Design